Ixico Regulatory News (IXI)

Director / PDMR Shareholding

Phytopharm PLC

("the Company" or "Phytopharm")

27 September 2013

Director's dealings

The Company today announces that it was notified on 26 September 2013 that, on the same day, Professor Derek Hill, CEO of IXICO Limited ("IXICO"), purchased 10,000 Ordinary Shares of 50p each in Phytopharm at a price of 56 pence per Ordinary Share.

On 23 September 2013, Phytopharm announced that terms had been agreed for the conditional acquisition of IXICO. The acquisition of IXICO is classified as a reverse takeover under the AIM Rules and is therefore conditional, inter alia, on the approval of Shareholders in a general meeting.

As a consequence of this share purchase, Professor Hill, a proposed Director of Phytopharm (to be renamed IXICO plc upon completion), has a total holding of 10,000 Ordinary Shares, representing 0.14% of Phytopharm's issued share capital. Following completion, Professor Hill's beneficial interest in the Company is expected to be 473,169 Ordinary Shares, representing 3.16% of the Company's enlarged issued share capital.

Enquiries

Phytopharm plc

Tim Sharpington, CEO

+44 1480 437 697

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel

Vijay Barathan

+44 207 418 8900

Investor Relations

FTI Consulting Limited

Ben Atwell

Simon Conway

John Dineen

+44 207 831 3113